Truist raised the firm’s price target on Edwards Lifesciences (EW) to $90 from $87 and keeps a Hold rating on the shares. The company delivered a solid Q3 revenue and earnings beat, marked by a return to 10% constant currency TAVR growth and a 2% TMTT beat while reflecting accelerating revenue growth, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target raised to $104 from $94 at Goldman Sachs
- Edwards Lifesciences price target raised to $90 from $85 at UBS
- Edwards Lifesciences price target raised to $84 from $81 at Canaccord
- Edwards Lifesciences upgraded to Outperform at Raymond James
- Edwards Lifesciences Reports Strong Earnings and Growth